a II-Spectrin Breakdown Product Cerebrospinal Fluid Exposure Metrics Suggest Differences in Cellular Injury Mechanisms after Severe Traumatic Brain Injury

Traumatic brain injury (TBI) produces aII-spectrin breakdown products (SBDPs) that are potential biomarkers for TBI. To further understand these biomarkers, the present study examined (1) the exposure and kinetic characteristics of SBDPs in cerebrospinal fluid (CSF) of adults with severe TBI, and (2) the relationship between these exposure and kinetic metrics and severity of injury. This clinical database study analyzed CSF concentrations of 150-, 145-, and 120-kDa SBDPs in 38 severe TBI patients. Area under the curve (AUC), mean residence time (MRT), maximum concentration (Cmax), time to maximum concentration (Tmax), and half-life (t1=2) were determined for each SBDP. Markers of calpain proteolysis (SBDP150 and SBDP145) had a greater median AUC and Cmax and a shorter MRT than SBDP120, produced by caspase-3 proteolysis in the CSF in TBI patients ( p < 0.001). AUC and MRT for SBDP150 and SBDP15 were significantly greater in patients with worse Glasgow Coma Scale (GCS) scores at 24 h after injury compared to those whose GCS scores improved (AUC p1⁄4 0.013, MRT p1⁄4 0.001; AUC p1⁄4 0.009, MRT p1⁄4 0.021, respectively). A positive correlation was found between patients with longer elevations in intracranial pressure (ICP) measurements of 25 mm Hg or higher and those with a greater AUC and MRT for all three biomarkers. This is the first study to show that the biomarkers of proteolysis differentially associated with calpain and caspase-3 activity have distinct CSF exposure profiles following TBI that suggest a prominent role for calpain activity. Further studies are being conducted to determine if exposure and kinetic metrics for biofluidbased biomarkers can predict clinical outcome.

[1]  D. Bennett,et al.  Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease. , 2008, The American journal of pathology.

[2]  C. Robertson,et al.  Clinical Significance of αII-Spectrin Breakdown Products in Cerebrospinal Fluid after Severe Traumatic Brain Injury , 2007 .

[3]  S. Yoshida,et al.  Serum S100B indicates brain edema formation and predicts long-term neurological outcomes in rat transient middle cerebral artery occlusion model , 2007, Brain Research.

[4]  M. Skalej,et al.  Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke , 2006, Clinical Neurology and Neurosurgery.

[5]  D. Lynch,et al.  Calpain and synaptic function , 2006, Molecular Neurobiology.

[6]  D. Sakas,et al.  Slight and short-lasting increase of serum S-100B protein in extra-cranial trauma , 2006, Brain injury.

[7]  T. Neumann-Haefelin,et al.  Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. , 2005, Archives of neurology.

[8]  J. Langlois,et al.  The Public Health Approach to Traumatic Brain Injury: An Overview of CDC's Research and Programs , 2005, The Journal of head trauma rehabilitation.

[9]  J. Langlois,et al.  Tracking the Silent Epidemic and Educating the Public: CDC's Traumatic Brain Injury—Associated Activities Under the TBI Act of 1996 and the Children's Health Act of 2000 , 2005, The Journal of head trauma rehabilitation.

[10]  S. Wisniewski,et al.  Continuous versus intermittent cerebrospinal fluid drainage after severe traumatic brain injury in children: effect on biochemical markers. , 2004, Journal of neurotrauma.

[11]  A. Eggermont,et al.  On the release and half‐life of S100B protein in the peripheral blood of melanoma patients , 2001, International journal of cancer.

[12]  Kevin K W Wang,et al.  Activation of apoptosis-linked caspase(s) in NMDA-injured brains in neonatal rats , 2000, Neurochemistry International.

[13]  Kevin K. W Wang,et al.  Calpain and caspase: can you tell the difference? , 2000, Trends in Neurosciences.

[14]  荒井保明 Pharmacokinetics , 1993 .